UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Universitätsbibliothek
Katalog
Details
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Datensatz exportieren als...
BibTeX
Functional significance of VEGFR‐2 on ovarian cancer cells
International journal of cancer, 2009-03, Vol.124 (5), p.1045-1053
Spannuth, Whitney A.
Nick, Alpa M.
Jennings, Nicholas B.
Armaiz‐Pena, Guillermo N.
Mangala, Lingegowda S.
Danes, Christopher G.
Lin, Yvonne G.
Merritt, William M.
Thaker, Premal H.
Kamat, Aparna A.
Han, Liz Y.
Tonra, James R.
Coleman, Robert L.
Ellis, Lee M.
Sood, Anil K.
2009
Details
Autor(en) / Beteiligte
Spannuth, Whitney A.
Nick, Alpa M.
Jennings, Nicholas B.
Armaiz‐Pena, Guillermo N.
Mangala, Lingegowda S.
Danes, Christopher G.
Lin, Yvonne G.
Merritt, William M.
Thaker, Premal H.
Kamat, Aparna A.
Han, Liz Y.
Tonra, James R.
Coleman, Robert L.
Ellis, Lee M.
Sood, Anil K.
Titel
Functional significance of VEGFR‐2 on ovarian cancer cells
Ist Teil von
International journal of cancer, 2009-03, Vol.124 (5), p.1045-1053
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2009
Link zum Volltext
Quelle
Electronic Journals Library
Beschreibungen/Notizen
Vascular endothelial growth factor receptor (VEGFR) has recently been discovered on ovarian cancer cells, but its functional significance is unknown and is the focus of this study. By protein analysis, A2780‐par and HeyA8 ovarian cancer cell lines expressed VEGFR‐1 and HeyA8 A2774, and SKOV3ip1 expressed VEGFR‐2. By in situ hybridization (ISH), 85% of human ovarian cancer specimens showed moderate to high VEGFR‐2 expression, whereas only 15% showed moderate to high VEGFR‐1 expression. By immunofluorescence, little or no VEGFR‐2 was detected in normal ovarian surface epithelial cells, whereas expression was detected in 75% of invasive ovarian cancer specimens. To differentiate between the effects of tumor versus host expression of VEGFR, nude mice were injected with SKOV3ip1 cells and treated with either human VEGFR‐2 specific antibody (1121B), murine VEGFR‐2 specific antibody (DC101) or the combination. Treatment with 1121B reduced SKOV3ip1 cell migration by 68% (p < 0.01) and invasion by 72% (p < 0.01), but exposure to VEGFR‐1 antibody had no effect. Treatment with 1121B effectively blocked VEGF‐induced phosphorylation of p130Cas. In vivo treatment with either DC101 or 1121B significantly reduced tumor growth alone and in combination in the SKOV3ip1 and A2774 models. Decreased tumor burden after treatment with DC101 or 1121B correlated with increased tumor cell apoptosis, decreased proliferative index, and decreased microvessel density. These effects were significantly greater in the combination group (p < 0.001). We show functionally active VEGFR‐2 is present on most ovarian cancer cells. The observed anti‐tumor activity of VEGF‐targeted therapies may be mediated by both anti‐angiogenic and direct anti‐tumor effects. © 2008 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0020-7136
eISSN: 1097-0215
DOI: 10.1002/ijc.24028
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668132
Format
–
Schlagworte
angiogenesis
,
Animals
,
Antibodies, Monoclonal - pharmacology
,
Antibodies, Monoclonal - therapeutic use
,
Apoptosis
,
Biological and medical sciences
,
Cell Proliferation
,
Crk-Associated Substrate Protein - physiology
,
Female
,
Female genital diseases
,
Gynecology. Andrology. Obstetrics
,
Humans
,
Medical sciences
,
Mice
,
ovarian carcinoma
,
Ovarian Neoplasms - blood supply
,
Ovarian Neoplasms - pathology
,
Ovarian Neoplasms - therapy
,
Signal Transduction
,
Tumors
,
Vascular Endothelial Growth Factor Receptor-2 - analysis
,
Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
,
Vascular Endothelial Growth Factor Receptor-2 - physiology
,
VEGFR
,
Xenograft Model Antitumor Assays
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX